Takeda, Twi move to dismiss US antitrust claims over Dexilant
MLex Summary: Takeda Pharmaceutical and Twi Pharmaceuticals moved to dismiss US claims that they entered into an illegal reverse payment agreement to restrain competition in the US market for Dexilant and...To view the full article, register now.
Already a subscriber? Click here to view full article